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THE foRowing considerations led us to carry out a trial of stilboestrol in acute
leukaemia. It is well know-n that the endocrine organs play an important part
in the regulation ofhaemopoiesis, and many workers have reported the beneficial
effects of ACTH and cortisone in some cases of this disease. Unfortunately,
however, remissions so induced areusuaRyonly ofshort duration. Re-treatment
may again have a beneficl'al effect, but eventually a refractory state is reached.
On the other hand, " myelokentric
" and
" lymphokentric
" acids, steroid-like
principles extracted from urine (Afiller and Turner, 1943) and from serum (Foster
and Miller, 1950) cause leukaemoid effects of myeloid and of lymphatic type
respectively when injected into normal animals. Furthermore, myelokentric
acid has induced partial remissions in human cases of lymphoblastic leukaemia
in the hands ofMiller, Herbutt and Jones (1947). Hence hormonal imbalance may
play a part in the aetiology of leukaemia.
Finkelstein, Gordon and Charipper (1944) demonstrated that oestrogens
have a depressant effect on the bone-marrow in certain conditions, but they did
not study leukaemic states.
Burrows and Horning (1952) have shown that not only are oestrogens careino-
aenic, but they may be careinostatic, often restraining and causing regression
of some humanneoplasms such as carcinomata of the breast and prostate. They
also state that the liabihty of mice to leucosis can be increased by oestrogens
and reduced by androgens. Furth (1952), however, reminds us that in most
strains of mice loukaemia is more common in the female, but in man it is more
common in males. It is possible, therefore, that in human leukaemia oestrogens
may have the opposite effect to that in niiee.
Dausset and Schwarzman (1951) reported astudy of 212 cases of acute leukae-
mia witb,regard to the influence ofage and sex upon thefrequency andcytological
types. They also reviewed other series in the literature from these points of
view, including both acute and chronic leukaemia. These authors state that
between 18 and 50 years in both males and females there is an overwhelrning
preponderance ofmyeloid leukaemia, while under the age of 18 and over the age
of 50 lymphoid leukaemia occurs almost exclusively. As the former occurs most
commonly during the period of maximal procreative activity, they suggest that
there may be an endocrine effect on the lymphatic-mye-loidequilibrium, especially
with regard to the sex hormones.
Stilb'oestrol appears to have had a beneficial effect in single cases of chronic
myeloid leukaemia (Loeper, LeSourd and Sterboul, 1947) and ofchroniclymphatic
leukaemia (Lemaire, Loeper, Housset and Koupernik, 1947). On the other hand256 E. K. BLACKBURN-
Laroche, Tremolieres, Dausset and Oury (I949) report a favourable effect with
high doses of testosterone in one case of acute myeloblastic leukaemia.
METHOD.
As the course of acute leukaemia, including the frequency of partial and
complete remissions, is well know-n (Bierman, Cohen, McCleHand and Shimkin,
1950 ; Rodgers, Donohue and Snelhng, 1951 ; Southam, Craver, Dargeon and
Burchenal, 1951), and any important modification as a result of treatment should
therefore become evident, the cases were not divided into treated patients and
untreated controls. Fifteen consecutive cases of acute leukaemia (8 witb the
myeloblastic and 7 with the monoblastic form) were treated with stilboestrol.
This was given orally, the dosage in general being 5 mg. t.d.s. increasing by 5 mor
total per day to 20 mg. t.d.s. Transfusion ofpacked red cells, antibiotic therapy,
oral hygiene and simple psychological treatment were adopted as the respective
clinical indications arose. Exchange transfusions and other remedies such as
X-rays, radiomimetic drugs, ACTH and cortisone, liver extracts, folic acid and
vitamin B12were not used.
Diagnosis in each case was madeby clinical and peripheral blood examinations
and confirmed by bone-marrow studies.
RESULTS.
These are sbown in Table I. The group of 15 patients consisted of II males
and 4females, their agesvarying between 2-1 and 67 years. The average duration 2 ofsymptomspriortotherapy wasapproximately 9weeks, and after the commence-
ment of treatment 48 days. No cases survived for more than 5 months after
therapy was begun, and none showed a complete remission.
Only 3 cases showed partial remissions as judged by objective signs of clinical
improvement (Cases 2, 6 and 10).
TABLE I.-Cases ofLeukaemia Treated with Stilboestral.
Duration of Survival Total
symptoms after com- amount of
Age before mencement Total stilboestrol
Case Type of in therapy oftherapy duration given, No. leukaemia. years. Sex. in weeks. in days. in weeks. in mg.
I 'Myeloblastic 46 F. 2 2 2 40
2 19 M. 6 152 28 4665
3 20 M. 5 91 18 12
4 49 F. 26 8 27 200
5 21 M. 3 27 7 725
6 20 F. 17 153 39 4462
7 20 M. 7 9 8 280
8 2i M. 80 54 16 287
9 Monoblastic 67 M. 17 4 18 140 10 91 53 M. 5 35 10 280 11 44 M. 5 6 6 120
12 37 M. 5 6 6 105 13 27 M. 13 15 15 225
14 15 M. 6 131 25 4442
15 44 F. 7 21 10 60
Bearing in mind that remissions iin acute leukaemia mayrarely bespontaneous,
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these 3 cases there was some suggestive evidence of transient benefit from stil-
boestrol itself. Case 2 had had penicillin therapy and three blood transfusions,
each oftwo bottles of blood, over a period of 20 days elsewhere without improve-
ment. His clinical condition had deteriorated, while the haemoglobin level had
fallen from 48per cent to 42 per cent, and the red cell count from 2-6 m. to 1-9 m.
per c.mm. during this time. On admission to hospital in Sheffield he was given
3 pints of packed cells and stilboestrol and penicillin therapy were begun. This
was followed by an excellent clinical remission for 6 weeks, with complete
disappearance of clinical splenomegaly and hepatomegaly, the latter organs
having been palpable 2 in. below the respective costal margins at the commence-
ment of treatment. Two days after the blood transfusion the haemoglobin
level was 8.9 g. per 100 ml. and the total leucocyte count 800 per c.mm. Over
the next few weeks his haemoglobin level rose to 12.6 g./100 ml., while the total
leucocyte count reached 6000 per c.mm., the only abnormal cell in the peripheral
blood being an occasional (1 per cent) blast form. When Case 6 was admitted
to hospital, she had gross gum hypertrophy, and a spleen palpable 11 in. below
the left costal margin. Her haemoglobin level was 7.8 g./100 ml. Ten days
after the commencement of stilboestrol therapy only, she was subjectively much
improved, the gum hypertrophy had diminished considerably, and the spleen
was impalpable, while the haemoglobin level had risen to 8.1 g./100 ml. Three
days later additional blood transfusion therapy was begun.
Stilboestrol was well tolerated in most cases, and toxic effects were few.
Nausea and vomiting led to the abandonment of this therapy in Case 13 after
5 days, while Cases 6 and 15 experienced transient nausea only in the first few
days of treatment. Slight mammary hypertrophy and increased areolar pigmen-
tation were noted in Cases 2, 3, 6 and 14.
SUMMARY AND CONCLUSIONS.
Fifteen cases of acute leukaemia (8 myeloblastic and 7 monoblastic) were
treated with stilboestrol. None lived for more than 5 months after beginning
therapy. No complete remissions occurred, but 3 patients had transient partial
remissions.
There is no evidence from this series to suggest that either the prognosis or
the clinical course of acute leukaemia is altered by adding stilboestrol to other
therapy.
I am indebted to my medical and surgical colleagues in Sheffield, to Dr. R. T.
Gaunt, of Chesterfield, and to Dr. Peter Milligan, of Doncaster, for referringtheir
cases. Thanks are also due to Professor E. J. Wayne and Dr. G. M. Wilson for
reading and criticising the manuscript.
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